SPDL1 inhibition enhances colorectal cancer progression via epidermal growth factor receptor/extracellular signal-regulated kinase pathways

doi:10.4251/wjgo.v17.i5.104686

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (620)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-2) series.

Item

Count

PDF

HTML

289

Figures (1-7)

108

Tables (1-2)

105

Sum=526

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=60

May 15, 2025 (publication date) through Jun 12, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. May 15, 2025; 17(5): 104686
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104686

Full Size Figure Download Figure

Figure 7 Proposed pathway by which reduced SPDL1 expression leads to epithelial-mesenchymal transition and promotes cell migration and invasion in colorectal cancer. EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; MEK: Mitogen-activated protein kinase; ERK: Extracellular signal-regulated kinase; EMT: Epithelial-mesenchymal transition.

Citation: Peng P, Sun J, Li MS, Cheng RX, Liu SQ, Qin MB, Zhang JX, Huang JA. SPDL1 inhibition enhances colorectal cancer progression via epidermal growth factor receptor/extracellular signal-regulated kinase pathways. World J Gastrointest Oncol 2025; 17(5): 104686
URL: https://www.wjgnet.com/1948-5204/full/v17/i5/104686.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.104686